Compugen to Present at the SVB Securities Global Biopharma Conference
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming presentation at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming presentation at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET. The event will be held virtually, and a live webcast will be accessible through the Investor Relations section of Compugen's website, with a replay available afterward.
Compugen is pioneering computational target discovery for cancer immunotherapies, with product candidates like COM701 and COM902. The company also has a partnered program, AZD2936, in Phase 2 development by AstraZeneca.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was -6.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON, Israel, Feb. 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the SVB Securities Global Biopharma Conference (virtual), on Thursday, February 16, 2023 at 9:20 AM ET.
A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen currently has one partnered program, namely AZD2936, a TIGIT/PD-1 bispecific derived from COM902, that is in Phase 2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is in pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-svb-securities-global-biopharma-conference-301742923.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.